Merck KGaA snatches up Geneva biotech as repurposed chemotherapy mission strikes a 'Chord'
About a year after Geneva-based Chord Therapeutics emerged from stealth to see if it could repurpose an old chemotherapy agent for rare diseases, Merck KGaA is swooping in with a buyout.
While the companies are keeping mum about the financial terms of the deal, Merck KGaA is adding Chord’s lead candidate to its neurology pipeline — a small molecule oral version of the chemotherapy drug cladribine dubbed CRD1.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.